Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined 4SC’s pivotal RESMAIN study (n=150) in CTCL, the company recruited the first patient in Japan. Top-line results from the RESMAIN trial are expected in mid-2019. In addition, Yakult initiated its own Phase II study in biliary tract cancer (n=100) in combination with S-1 chemotherapy. S-1 is widely used in Japan and other Asian countries
03 May 2018
4SC - Yakult starts Phase II trial; fresh 4SC-202 data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
4SC - Yakult starts Phase II trial; fresh 4SC-202 data
4SC AG (VSC:FRA) | 0 0 4.2% | Mkt Cap: 249.2m
- Published:
03 May 2018 -
Author:
Dr Jonas Peciulis -
Pages:
5
Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined 4SC’s pivotal RESMAIN study (n=150) in CTCL, the company recruited the first patient in Japan. Top-line results from the RESMAIN trial are expected in mid-2019. In addition, Yakult initiated its own Phase II study in biliary tract cancer (n=100) in combination with S-1 chemotherapy. S-1 is widely used in Japan and other Asian countries